At the conclusion of this activity, learners should be able to:

  • Understand the basis and clinical relevance of PD-L1 immunohistochemical scoring in non-small cell lung carcinoma
  • Become familiar with LAG-3 as a biomarker and immunotherapy target in non-small cell lung carcinoma
Add to calendar: 
Session date: 
12/10/2021 - 12:00pm to 1:00pm EST

Please login or register to take this course.
Room Number: 
Zoom Meeting
Speaker Name: 
Daniel Shepherd, MD, PhD, Massachusetts General Hospital